多奈哌齐N氧化物 | 120013-84-5

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 多奈哌齐N氧化物
• 中文别名: 2,3-二氢-5,6-二甲氧基-2-[[1-(苯基甲基)-4-哌啶基]甲基]-1H-茚-1-酮N-氧化物
• 英文名称: rac (cis/trans) Donepezil N-Oxide
• 英文别名: 2-[(1-benzyl-1-oxidopiperidin-1-ium-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
• CAS: 120013-84-5；147427-78-9；147427-77-8
• 化学式: C24H29NO4
• 分子量: 395.5
• InChiKey: XRPRYHONRUINMG-UHFFFAOYSA-N

物化性质

• 熔点：
  190-192°C
• 溶解度：
  可溶于氯仿、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  53.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• TRANSDERMAL ABSORPTION PREPARATION CONTAINING STABILIZED DONEPEZIL
  申请人：Dong-A St Co., Ltd.

  公开号：EP3900711A1

  公开（公告）日：2021-10-27

  The present invention relates to a percutaneous absorption preparation comprising donepezil for the treatment of dementia. More specifically, the present invention relates to a percutaneous absorption preparation for the treatment of dementia comprising a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer comprises donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. The present invention provides a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.

  本发明涉及一种用于治疗痴呆症的包含多奈哌齐的经皮吸收制剂。更具体地说，本发明涉及一种治疗痴呆症的经皮吸收制剂，包括支撑层、含药层和释放层，其中含药层包括作为活性成分的多奈哌齐或其药学上可接受的盐；作为稳定剂的单硫代甘油、硫氰酸金属盐（优选钾盐）或二甲基硫脲；以及压敏胶。 本发明提供了一种治疗痴呆症的经皮吸收制剂，减少了多奈哌齐杂质的形成。
• Neurocyte protective agent
  申请人：Akasofu Shigeru

  公开号：US20070021397A1

  公开（公告）日：2007-01-25

  A protective agent for neurons of the central nervous system and a prophylactic and/or therapeutic agent for disorders in neurons of the central nervous system is provided, each including a compound represented by donepezil hydrochloride.
• SUSTAINED RELEASE DONEPEZIL FORMULATIONS
  申请人：Movva Snehalatha

  公开号：US20130059003A1

  公开（公告）日：2013-03-07

  Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations.
• PERCUTANEOUS ABSORPTION PREPARATION COMPRISING STABILIZED DONEPEZIL
  申请人：DONG-A ST CO., LTD

  公开号：US20220047524A1

  公开（公告）日：2022-02-17

  A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.
• [EN] SUSTAINED RELEASE DONEPEZIL FORMULATIONS<br/>[FR] FORMULATION DE DONÉPÉZIL À LIBÉRATION PROLONGÉE
  申请人：REDDYS LAB LTD DR

  公开号：WO2011069076A2

  公开（公告）日：2011-06-09

  Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations.